Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Journal of the American Statistical Association
|
June 26, 2015
Size and Shape Analysis of Error-Prone Shape Data
Jiejun Du, Ian L Dryden, Xianzheng Huang
The Journal of Antimicrobial Chemotherapy
|
June 3, 2017
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims, Valeri Mariyanovski, Patrick McLeroth, et al.
Infectious Diseases and Therapy
|
April 25, 2024
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Infectious Diseases and Therapy
|
November 23, 2023
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Open Forum Infectious Diseases
|
June 29, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, et al.
Jac-Antimicrobial Resistance
|
March 7, 2023
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance
Jason A Roberts, David P Nicolau, Ignacio Martin-Loeches, et al.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections
Keith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Open Forum Infectious Diseases
|
March 11, 2020
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
Michelle L Brown, Johann Motsch, Keith S Kaye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Yanfen Guan, Amy Puenpatom, Matthew G Johnson, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Journal of the American Statistical Association
|
June 26, 2015
Size and Shape Analysis of Error-Prone Shape Data
Jiejun Du, Ian L Dryden, Xianzheng Huang
The Journal of Antimicrobial Chemotherapy
|
June 3, 2017
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims, Valeri Mariyanovski, Patrick McLeroth, et al.
Infectious Diseases and Therapy
|
April 25, 2024
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Infectious Diseases and Therapy
|
November 23, 2023
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Open Forum Infectious Diseases
|
June 29, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, et al.
Jac-Antimicrobial Resistance
|
March 7, 2023
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance
Jason A Roberts, David P Nicolau, Ignacio Martin-Loeches, et al.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections
Keith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Open Forum Infectious Diseases
|
March 11, 2020
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
Michelle L Brown, Johann Motsch, Keith S Kaye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Yanfen Guan, Amy Puenpatom, Matthew G Johnson, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Page
of 3